Literature DB >> 1748139

Effect of pentoxifylline on liver plasma flow in normal man.

A Suren1, F E Bauer, B Rosenkranz, J Bircher.   

Abstract

In ten healthy, male subjects the acute effect of pentoxifylline (a methylxanthine derivative) on liver plasma flow was investigated by the extrarenal sorbitol clearance method and on cardiac output by impedance cardiography. On the placebo day liver plasma flow decreased within 4 h from 769 to 683 ml.min-1 (P less than 0.05) and on the pentoxifylline day (300 mg i.v.) it increased from 764 to 801 ml.min-1 (NS). At the end of the experiment the difference between the groups was also significant (P less than 0.05). There was no significant change in cardiac output, blood pressure or heart rate and individual changes in those values were not correlated with liver plasma flow. There was no correlation either between the plasma concentrations of pentoxifylline or its metabolites and the changes in liver plasma flow. It is concluded that, relative to the spontaneous decrease in liver plasma flow at rest on the placebo day, pentoxifylline increased splanchnic perfusion independent of any change in cardiac output.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748139     DOI: 10.1007/BF00315435

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow.

Authors:  J Zeeh; H Lange; J Bosch; S Pohl; H Loesgen; R Eggers; M Navasa; J Chesta; J Bircher
Journal:  Gastroenterology       Date:  1988-09       Impact factor: 22.682

2.  Effects of physical stress on the disposition of drugs eliminated by the liver in man.

Authors:  R D Swartz; F R Sidell; S A Cucinell
Journal:  J Pharmacol Exp Ther       Date:  1974-01       Impact factor: 4.030

3.  Regional blood flow determination in rats by the microsphere method during i.v. infusion of vasodilating agents.

Authors:  F Vetterlein; R Halfter; G Schmidt
Journal:  Arzneimittelforschung       Date:  1979

Review 4.  Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication.

Authors:  H R Dettelbach; D M Aviado
Journal:  J Clin Pharmacol       Date:  1985 Jan-Feb       Impact factor: 3.126

5.  Pharmacologic treatment of intermittent claudication.

Authors:  J M Porter; G M Bauer
Journal:  Surgery       Date:  1982-12       Impact factor: 3.982

6.  Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism.

Authors:  A J McLean; P J McNamara; P duSouich; M Gibaldi; D Lalka
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

7.  Physiological and pharmacological variability in estimated hepatic blood flow in man.

Authors:  T K Daneshmend; L Jackson; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

8.  [The effect of pentoxifylline on liver perfusion: a comparative study in patients with liver diseases and in normal subjects, using 198Au-colloid-scintigraphy (author's transl)].

Authors:  K Koppenhagen; H G Wenig
Journal:  Med Klin       Date:  1979-08-31

9.  Lidocaine kinetics predicted by indocyanine green clearance.

Authors:  R A Zito; P R Reid
Journal:  N Engl J Med       Date:  1978-05-25       Impact factor: 91.245

10.  Effect of pentoxifylline on regional cerebral blood flow in patients with cerebral vascular disorders.

Authors:  A Hartmann
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

View more
  2 in total

1.  Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis.

Authors:  C Raetsch; J D Jia; G Boigk; M Bauer; E G Hahn; E-O Riecken; D Schuppan
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

2.  Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression.

Authors:  Jing Wu; Miao-yun Zhao; Hao Zheng; Hua Zhang; Ying Jiang
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.